Mainz Biomed (MYNZ) Competitors $6.09 +0.75 (+14.04%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$6.49 +0.40 (+6.63%) As of 01/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MYNZ vs. ELEV, INKT, OKYO, UBX, OCX, CVKD, RNXT, XLO, VRCA, and CVMShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Elevation Oncology (ELEV), MiNK Therapeutics (INKT), OKYO Pharma (OKYO), Unity Biotechnology (UBX), OncoCyte (OCX), Cadrenal Therapeutics (CVKD), RenovoRx (RNXT), Xilio Therapeutics (XLO), Verrica Pharmaceuticals (VRCA), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Elevation Oncology MiNK Therapeutics OKYO Pharma Unity Biotechnology OncoCyte Cadrenal Therapeutics RenovoRx Xilio Therapeutics Verrica Pharmaceuticals CEL-SCI Elevation Oncology (NASDAQ:ELEV) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation. Is ELEV or MYNZ more profitable? Mainz Biomed's return on equity of 0.00% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -59.73% -40.05% Mainz Biomed N/A N/A N/A Does the media favor ELEV or MYNZ? In the previous week, Mainz Biomed had 6 more articles in the media than Elevation Oncology. MarketBeat recorded 9 mentions for Mainz Biomed and 3 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.22 beat Mainz Biomed's score of -0.11 indicating that Elevation Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevation Oncology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer ELEV or MYNZ? Elevation Oncology presently has a consensus target price of $7.20, indicating a potential upside of 938.66%. Mainz Biomed has a consensus target price of $120.00, indicating a potential upside of 1,870.44%. Given Mainz Biomed's higher possible upside, analysts clearly believe Mainz Biomed is more favorable than Elevation Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Mainz Biomed 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, ELEV or MYNZ? Elevation Oncology has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Does the MarketBeat Community prefer ELEV or MYNZ? Elevation Oncology received 22 more outperform votes than Mainz Biomed when rated by MarketBeat users. Likewise, 76.09% of users gave Elevation Oncology an outperform vote while only 72.22% of users gave Mainz Biomed an outperform vote. CompanyUnderperformOutperformElevation OncologyOutperform Votes3576.09% Underperform Votes1123.91% Mainz BiomedOutperform Votes1372.22% Underperform Votes527.78% Which has preferable valuation and earnings, ELEV or MYNZ? Mainz Biomed has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$45.70M-$0.82-0.85Mainz Biomed$900K13.53-$26.30M-$65.60-0.09 Do insiders & institutionals have more ownership in ELEV or MYNZ? 83.7% of Elevation Oncology shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryElevation Oncology and Mainz Biomed tied by winning 8 of the 16 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.11M$6.86B$5.58B$9.11BDividend YieldN/A2.90%5.32%3.99%P/E Ratio-0.099.6789.2618.26Price / Sales13.53301.931,254.4080.65Price / CashN/A73.5045.9637.70Price / Book0.565.275.124.70Net Income-$26.30M$136.98M$111.40M$224.47M7 Day Performance36.85%-0.73%2.33%-0.20%1 Month Performance40.97%0.16%3.20%0.57%1 Year Performance-83.97%7.59%24.64%20.29% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.8697 of 5 stars$6.09+14.0%$120.00+1,870.4%-84.3%$10.11M$900,000.00-0.0930Short Interest ↓Gap UpHigh Trading VolumeELEVElevation Oncology2.3641 of 5 stars$0.61-7.2%$7.20+1,072.6%-75.1%$35.71MN/A-0.7440Short Interest ↑INKTMiNK Therapeutics3.4061 of 5 stars$0.90-4.2%$6.50+626.3%+5.9%$35.47MN/A-2.2930Stock SplitShort Interest ↓OKYOOKYO Pharma3.1642 of 5 stars$1.05-0.5%$7.00+569.9%-27.9%$35.36MN/A0.007News CoverageUBXUnity Biotechnology4.569 of 5 stars$2.09-12.4%$7.33+251.7%+28.3%$34.88M$240,000.00-1.5860OCXOncoCyte3.5101 of 5 stars$2.07+1.7%$4.42+113.9%-33.2%$34.75M$1.50M0.00120Gap UpCVKDCadrenal Therapeutics3.5322 of 5 stars$19.61+1.4%$32.00+63.2%N/A$34.59MN/A-2.914Short Interest ↓RNXTRenovoRx2.1942 of 5 stars$1.39+0.4%$6.50+369.3%-9.3%$33.24MN/A-2.436XLOXilio Therapeutics3.7363 of 5 stars$0.75-8.9%$4.00+435.5%+8.5%$32.93MN/A-0.4470Short Interest ↓News CoverageVRCAVerrica Pharmaceuticals4.5989 of 5 stars$0.72-0.2%$9.50+1,217.6%-88.5%$32.83M$5.12M-0.3940Positive NewsGap UpCVMCEL-SCIN/A$0.45+8.4%N/A-86.4%$32.83MN/A-0.8743Analyst Forecast Related Companies and Tools Related Companies Elevation Oncology Alternatives MiNK Therapeutics Alternatives OKYO Pharma Alternatives Unity Biotechnology Alternatives OncoCyte Alternatives Cadrenal Therapeutics Alternatives RenovoRx Alternatives Xilio Therapeutics Alternatives Verrica Pharmaceuticals Alternatives CEL-SCI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYNZ) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
